Webinar
16:00 - 17:00pm 15 April 2021 (GMT+8 China Time)
The global market for the outlook and manufacture of APIs is shifting as more complex or potent ingredients evolve which present specific handling and manufacturing challenges. What are the latest technological approaches for these products, and how can quality, safety and cost be managed and improved upon? A key impact of the pandemic has been to question the reliance and dependence on Asia as the global leader of API manufacturing. Do we expect to see specific regions implement reshoring of manufacturing efforts? How will global supply chains be impacted? Join us as we tackle key trends and dynamics of the API manufacturing sector in just 60 minutes.
● Understand the API manufacturing landscape and key sector trends
● See how the pandemic has impacted API manufacturing globally
● Learn about the realities of shifting manufacturing hubs and reshoring manufacturing
● Hear predictions on what the future of API manufacturing looks like
● Get an overview of deal making and M&A
Stuart E. Needleman
Chief Commercial Officer, Piramal Pharma Solutions
Stuart Needleman is responsible for driving all global business development
activities for the services business, ranging from discovery services to commercial
supply, in both drug substance and drug products.
Stuart Needleman is responsible for driving all global business development activities for the services business, ranging from discovery services to commercial supply, in both drug substance and drug products.
Gianluca Franguelli
Vice President of Drug Development, Recipharm
After spending a couple of decades in sales and marketing roles for several
international API manufacturers, Gianluca contributed a few years ago, creating a
unique Center of Excellence at Recipharm dedicated to drug substance development.
After spending a couple of decades in sales and marketing roles for several international API manufacturers, Gianluca contributed a few years ago, creating a unique Center of Excellence at Recipharm dedicated to drug substance development.
Molly Bowman
Editorial Director at Clarivate Analytics
Molly Bowman has over 10 years’ experience in the life sciences industry supporting
companies in the global generic sector. She is currently responsible for overseeing
content collection and integration of Cortellis for Generics Intelligence product
suite.
Molly Bowman has over 10 years’ experience in the life sciences industry supporting companies in the global generic sector. She is currently responsible for overseeing content collection and integration of Cortellis for Generics Intelligence product suite.
Trends in Global API Manufacturing
Molly Bowman, Editorial Director, Clarivate Analytics
● Market Outlook for APIs (Market sizing, geography of API manufacturing)
● Trends and shifts in manufacturing hubs. Can we expect a reshoring of API
manufacturing? Will hubs shift from Asia?
Trends in Small Molecule API Manufacturing at CDMOs and Integrated Services
Stuart E. Needleman, Chief Commercial Officer, Piramal Pharma Solutions
● API market outlook
● on-shoring/re-shoring of services
● Impact of covid
● API manufacturing as part of an integrated services program
● What it means to be a patient-centric CDMO
Small Molecules - A Fast Changing Contest Driven by Novel Advanced Manufacturing Models
Gianluca Franguelli, Vice President of Drug Development, Recipharm
JENNIFER YANG
+86-21-3339 2533
Jennifer.Yang@imsinoexpo.com
FEATURED
HOSTED BUYERS
INDUSTRY
Presented by
China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)
Presented by
IQVIA